If you want access to our entire Portfolio and all our current Top Picks, feel free to join us for a 2-week free trial at High Yield Landlord.It seemed to have been triggered by the Fed's changed "dot plot" forecast from three rate cuts next year to two. Was that enough to cause such a selloff?Austin is a contributing author for the investing group High Yield Landlord , one of the largest real estate investment communities on Seeking Alpha, with thousands of members. It offers exclusive research on the glob ...

In 2022 and 2023, rising interest rates drove up the yields of low-risk fixed income investments like Treasury bills, bonds, and CDs, which made them more appealing than dividend stocks. But as interest rates decline, those fixed income yields are shrinking and driving more investors back toward higher-yielding dividend stocks.One of those stocks is Agree Realty (ADC 1.05%), which has gained about 14% during the past 12 months but still pays an attractive forward yield of 4.3%. Let's see if it's the right t ...

Agree Realty (ADC 1.05%) has been a popular stock in 2024, with a share price gain of more than 15%. That's roughly three times the return of the average real estate investment trust (REIT). Although Agree's dividend yield is above the REIT average at around 4% (versus the 3.7% average), it might be time to consider a value-conscious alternative. Here's the biggest option that you should be looking at today. There are a lot of reasons to like Agree RealtyAgree Realty is a very well-run net lease REIT (a net ...

Core Insights - Aadi Bioscience has entered into an exclusive license agreement for a three-asset antibody-drug conjugate (ADC) portfolio developed in collaboration with WuXi Biologics and HANGZHOU DAC, focusing on preclinical ADC programs targeting PTK7, MUC16, and SEZ6 [1][2] - The company is selling its FYARRO product and associated infrastructure to KAKEN Pharmaceutical for $100 million, with the transaction expected to close in the first half of 2025 [11][12] - Aadi has announced a PIPE financing of $100 million to support its operations and fund the ADC portfolio development into late 2028 [3][14] License Agreement Details - Aadi will pay $44 million in upfront payments for the ADC programs and is obligated to pay up to $265 million in development milestone payments and up to $540 million in commercial milestone payments, along with single-digit royalties on sales [2] - The ADC assets utilize HANGZHOU DAC's CPT113 platform, which features a stable yet cleavable linker delivering a Topoisomerase I inhibitor payload, positioning them competitively among next-generation ADC platforms [6][7] Financial Transactions - The PIPE financing involves the sale of 21,592,000 shares at $2.40 per share, representing a 3.4% premium to the closing price on December 19, 2024 [3][4] - The net proceeds from the PIPE financing and the sale of FYARRO are expected to fund operations into late 2028, including anticipated clinical data readouts for the ADC portfolio [14] Management and Board Changes - Baiteng Zhao, co-founder and former CEO of ProfoundBio, has been appointed to Aadi's Board of Directors, bringing significant expertise in ADC development [15][16] - Zhao expressed optimism about the potential of the ADC targets and the advanced linker-payload platform, indicating Aadi's strong position to impact patient outcomes [17] Product and Market Focus - The ADC portfolio targets tumor markers that are overexpressed in various cancers, including non-small cell lung cancer and cancers of female origin, aiming to improve treatment outcomes [7][8] - The collaboration with WuXi Biologics and HANGZHOU DAC emphasizes the innovative approaches in ADC development, leveraging advanced discovery technologies [10]

Mersana Therapeutics (NASDAQ: MRSN ) is an early phase biotech that has faced challenges in recent years, having shelved several once-promising clinical candidates. In my first outing on the company, I suggested that theyI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitf ...

Dividend growth stocks aren't always the most exciting investments out there. They often aren't grabbing the headlines, and they aren't theFor some background on this monthly publication, here is my view on dividend growth stocks :Interested in more income ideas? Check out Cash Builder Opportunities, where we provide ideas about high-quality and reliable dividend growth ideas. These investments are designed to build growing income for investors. A special focus on investments that are leaders within their i ...

Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, BDC's, and REITs. I am a buy-and-hold investor who prefers quality over quantity and plans to supplement his retirement income ...

Net lease real estate investment trust (REIT) Agree Realty (ADC 1.39%) has a 4.1% dividend yield. That yield is a little higher than the 3.7% average for the REIT sector, but below the 5.6% you could get from buying industry leading net lease REIT Realty Income. Is Agree Realty worth the premium price for investors looking to build seven-figure portfolios? Maybe.What is a net lease REIT?A net lease requires tenants to pay most property-level operating costs. Net lease assets are usually leased to a single t ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload –-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload --– Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 –BOSTON, Dec. 12, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...